StockNews.AI
OCUL
StockNews.AI
176 days

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

1. Conference call scheduled March 3, 2025, for Q4 and full-year financial results. 2. Call details include dial-in and webcast access for investor review. 3. AXPAXLI remains in Phase 3 for wet AMD, signaling key pipeline progress. 4. Pipeline also highlights FDA-approved DEXTENZA and ongoing PAXTRAVA trials.

4m saved
Insight
Article

FAQ

Why Neutral?

This announcement is routine, setting up an earnings call where results are expected. Historically, such updates drive short-term volatility but generally align with market expectations.

How important is it?

The call is critical for disclosing detailed financial and business progress, yet the anticipated results are within expectations, moderating impact.

Why Short Term?

Earnings releases and conference calls typically affect immediate trading. Similar events in biotech have shown short-lived price movements around the announcement.

Related Companies

OCUL
February 24, 2025 07:00 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow the Company on its website, LinkedIn, or X. The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

Related News